"Graft vs Leukemia Effect" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Immunological rejection of leukemia cells following bone marrow transplantation.
| Descriptor ID |
D020544
|
| MeSH Number(s) |
G12.875.402.320.320
|
| Concept/Terms |
Graft vs Leukemia Effect- Graft vs Leukemia Effect
- Graft-vs-Leukemia Response
- Graft-vs-Leukemia Responses
- Response, Graft-vs-Leukemia
- Responses, Graft-vs-Leukemia
- Graft vs Leukemia Response
- Graft-vs-Leukemia Effect
- Effect, Graft-vs-Leukemia
- Effects, Graft-vs-Leukemia
- Graft-vs-Leukemia Effects
|
Below are MeSH descriptors whose meaning is more general than "Graft vs Leukemia Effect".
Below are MeSH descriptors whose meaning is more specific than "Graft vs Leukemia Effect".
This graph shows the total number of publications written about "Graft vs Leukemia Effect" by people in this website by year, and whether "Graft vs Leukemia Effect" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 0 | 1 | 1 |
| 2005 | 1 | 1 | 2 |
| 2007 | 1 | 1 | 2 |
| 2008 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 1 | 1 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2020 | 2 | 0 | 2 |
| 2021 | 2 | 1 | 3 |
| 2022 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Graft vs Leukemia Effect" by people in Profiles.
-
Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):e105-9.
-
Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant. Leukemia. 2013 Jul; 27(7):1538-47.
-
Common minor histocompatibility antigen discovery based upon patient clinical outcomes and genomic data. PLoS One. 2011; 6(8):e23217.
-
Immunotherapy of AML. Cancer Treat Res. 2010; 145:237-55.
-
Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse. Biol Blood Marrow Transplant. 2009 Nov; 15(11):1475-8.
-
Dasatinib may not suppress the GVL effect of donor lymphocyte infusions for CML. Bone Marrow Transplant. 2010 Feb; 45(2):395-6.
-
Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. Clin Lymphoma Myeloma. 2009; 9 Suppl 3:S261-5.
-
Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation. Best Pract Res Clin Haematol. 2008 Sep; 21(3):437-53.
-
Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia. Blood. 2007 Sep 15; 110(6):1924-32.
-
High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects. Blood. 2007 Jul 15; 110(2):770-5.